EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report

EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report

Lineage transformation from lung adenocarcinoma (LUAD) to SCLC is associated with resistance to EGFR tyrosine kinase inhibitors. In addition to loss of p53 and RB, transformed SCLCs are usually not dependent on EGFR signaling, which renders the tumors unresponsive to EGFR tyrosine kinase inhibitors....

Full description

Bibliographic Details
Main Authors: Sho Takuma, MD, Yusuke Inoue, MD, PhD, Masato Karayama, MD, PhD, Kazuo Tsuchiya, MD, Hiroe Tsukui, MD, Hironao Hozumi, MD, PhD, Yuzo Suzuki, MD, PhD, Kazuki Furuhashi, MD, PhD, Noriyuki Enomoto, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Yutaro Nakamura, MD, PhD, Naoki Inui, MD, PhD, Takafumi Suda, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:JTO Clinical and Research Reports
Subjects:
Spontaneous transformation
Neuroendocrine
EGFR
Small cell lung cancer
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321001235

Similar Items

Similar Items